MeSH Browser

MeSH Heading: Hyperlipoproteinemia Type III
Tree Number(s): C16.320.565.398.483; C18.452.584.500.500.644.485; C18.452.584.563.483; C18.452.648.398.483
Unique ID: D006952
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D006952
Scope Note: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
Entry Term(s): Broad Beta Disease; Dysbetalipoproteinemia; Dysbetalipoproteinemia, Familial; Familial Dysbetalipoproteinemia; Familial Hypercholesterolemia with Hyperlipemia; Hyperlipoproteinemia, Broad-beta; Hyperlipoproteinemia, Type III
Previous Indexing: Hyperlipidemia/familial & genetic (1966-1979)
Public MeSH Note: 80
History Note: 80
Date Established: 1980/01/01
Date of Entry: 1979/04/23
Revision Date: 2021/06/30

Allowable Qualifiers: blood (BL)

cerebrospinal fluid (CF)

chemically induced (CI)

classification (CL)

complications (CO)

diagnosis (DI)

diagnostic imaging (DG)

diet therapy (DH)

drug therapy (DT)

economics (EC)

embryology (EM)

enzymology (EN)

epidemiology (EP)

ethnology (EH)

etiology (ET)

genetics (GE)

history (HI)

immunology (IM)

metabolism (ME)

microbiology (MI)

mortality (MO)

nursing (NU)

parasitology (PS)

pathology (PA)

physiopathology (PP)

prevention & control (PC)

psychology (PX)

radiotherapy (RT)

rehabilitation (RH)

surgery (SU)

therapy (TH)

urine (UR)

veterinary (VE)

virology (VI)

Concept UI: M0010834
Scope Note: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
Terms: Hyperlipoproteinemia Type III Preferred Term
Term UI T020886
Date01/01/1999
LexicalTag NON
ThesaurusID NLM (1980); Dysbetalipoproteinemia
Term UI T020885
Date04/23/1979
LexicalTag NON
ThesaurusID UNK (19XX); Hyperlipoproteinemia, Type III
Term UI T824545
Date06/22/2012
LexicalTag NON
ThesaurusID OMIM (2013); Dysbetalipoproteinemia, Familial
Term UI T646161
Date07/18/2005
LexicalTag NON
ThesaurusID NLM (2007); Familial Hypercholesterolemia with Hyperlipemia
Term UI T646572
Date07/21/2005
LexicalTag NON
ThesaurusID; Familial Dysbetalipoproteinemia
Term UI T662325
Date12/16/2005
LexicalTag NON
ThesaurusID NLM (2007); Broad Beta Disease
Term UI T020884
Date04/23/1979
LexicalTag NON
ThesaurusID UNK (19XX); Hyperlipoproteinemia, Broad-beta
Term UI T646160
Date07/18/2005
LexicalTag NON
ThesaurusID NLM (2007)

Hyperlipoproteinemia Type III MeSH Descriptor Data 2022